A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC.
JTO Clin Res Rep
; 3(12): 100416, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-36426287
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Year:
2022
Type:
Article